Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition
暂无分享,去创建一个
A. Toubert | P. Cattan | M. Allez | L. Maggiori | R. Remark | T. Aparicio | M. Bléry | C. Bonnafous | J. Lavolé | F. Bouhidel | V. Chardiny | Tristan Courau | J. Bonnereau | L. Le Bourhis | N. Hammoudi | P. Bhat | Nicolas Asesio | Hélène Corté | Delphine Salfati | Sarah Hamoudi | J. Vivier-Chicoteau | T. Courau | H. Corté | N. Asesio | D. Salfati
[1] K. Ouyang,et al. A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment , 2021 .
[2] G. Coukos,et al. Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed autologous tumoroids , 2021, bioRxiv.
[3] P. Gibbs,et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.
[4] J. Powers,et al. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ecto-Nucleotidases CD73 and CD39. , 2020, Journal of medicinal chemistry.
[5] Matthias P. Lutolf,et al. High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays , 2020, Nature Biomedical Engineering.
[6] Yue Zhang,et al. Advances in immunotherapy for colorectal cancer: a review , 2020, Therapeutic advances in gastroenterology.
[7] A. Broeks,et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.
[8] S. Gruber,et al. The Prognostic Implications of Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Systematic Review and Meta-Analysis , 2020, Scientific Reports.
[9] D. Allard,et al. On the mechanism of anti-CD39 immune checkpoint therapy , 2020, Journal for ImmunoTherapy of Cancer.
[10] Bridget A. Baxter,et al. Metabolite profile comparisons between ascending and descending colon tissue in healthy adults , 2020, World journal of gastroenterology.
[11] Zaozao Wang,et al. Phenotype molding of T cells in colorectal cancer by single‐cell analysis , 2020, International journal of cancer.
[12] E. Cuppen,et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients , 2019, Science Translational Medicine.
[13] Song Liu,et al. Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer , 2019, Scientific Reports.
[14] Qin Li,et al. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy , 2019, Journal of Hematology & Oncology.
[15] A. Roussel,et al. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. , 2019, Cell reports.
[16] A. Toubert,et al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment , 2019, Journal of Immunotherapy for Cancer.
[17] B. Gustavsson,et al. CD39+ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function , 2018, Oncotarget.
[18] M. Najafi,et al. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.
[19] Hans Clevers,et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids , 2018, Cell.
[20] B. Fox,et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors , 2018, Nature Communications.
[21] K. Jirström,et al. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis , 2018, Oncoimmunology.
[22] M. Fehlings,et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.
[23] D. Sansom,et al. CTLA-4: a moving target in immunotherapy. , 2018, Blood.
[24] Yan Kang,et al. What Else Can CD39 Tell Us? , 2017, Front. Immunol..
[25] Xi-chen Zhang,et al. Bovine Polymorphonuclear Neutrophils Cast Neutrophil Extracellular Traps against the Abortive Parasite Neospora caninum , 2017, Front. Immunol..
[26] S. M. Toor,et al. Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer , 2017, Front. Immunol..
[27] S. Robson,et al. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets , 2017, Immunological reviews.
[28] I. Pacella,et al. Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer , 2016, Oncoimmunology.
[29] L. Zitvogel,et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] Z. Trajanoski,et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.
[31] Y. Ben-Neriah,et al. Inflammatory networks underlying colorectal cancer , 2016, Nature Immunology.
[32] B. Gustavsson,et al. Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism , 2016, Cancer Immunology Research.
[33] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Zitvogel,et al. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? , 2015, Oncoimmunology.
[35] William W. Agace,et al. Regional specialization within the intestinal immune system , 2014, Nature Reviews Immunology.
[36] I. Frazer,et al. The Kinematics of Cytotoxic Lymphocytes Influence Their Ability to Kill Target Cells , 2014, PloS one.
[37] E. Tartour,et al. Colorectal cancer and immunity: what we know and perspectives. , 2014, World journal of gastroenterology.
[38] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[39] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[40] Hans Clevers,et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.
[41] H. Friess,et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer , 2011, Purinergic Signalling.
[42] L. Saltz,et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Fleuren,et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer , 2001, Histochemistry and Cell Biology.